Overview

Cholesterol Metabolites as Markers for CYP3A Induction

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are: - To investigate if the endogenous cholesterol metabolite, 4beta-OHcholesterol could be used as a marker for induction of cytochrome P450 (CYP) 3A4. - To compare 4beta-OHcholesterol with midazolam as a marker for induction of CYP3A4.
Phase:
N/A
Details
Lead Sponsor:
Karolinska University Hospital
Collaborator:
AstraZeneca
Treatments:
Midazolam
Rifampin